Protocol Specific Research

协议特定研究

• 批准号: 8321647
• 负责人: STEPHEN D WILLIAMS
• 金额: $ 5.79万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8321647
• 关键词: Cancer Center; Cancer Center Support Grant; Clinic; Clinical Investigator; Clinical Nursing Research; Clinical Research; Clinical Trials; Collaborations; Correlative Study; Data; Devices; Faculty; Funding; Future; Genomics; Indiana; Individual; Laboratories; Malignant Neoplasms; Molecular Biology; Nursing Research; Patients; Peer Review; Phase; Pilot Projects; Prevention; Process; Proteomics; Protocols documentation; Research; Research Personnel; Resources; Science; Source; Specialist; Testing; Universities; Update; cancer therapy; cost; innovation; member; programs

Advances in many aspects of science including molecular biology, genomics and proteomics have resulted in significant advances in defining the causes of and new treatments for cancer. Close collaborations are needed to take advances from the laboratory into the clinic. These collaborations and resources available to conduct translational clinical research have been very productive during the current funding period. Currently, the CCSG provides funding for 0.25 FTE research nurse and 0.5 FTE clinical research specialist (CRS). The IU Simon Cancer Center has allocated this money by a process described in detail below to support investigatorinitiated Phase I and pilot studies that are highly meritorious. The ID Simon Cancer Center also provided additional funds from other sources for the conduct of these trials. We anticipate growing numbers of patients accrued to future phase I and pilot studies because of the recruitment during the current funding period of translational clinical investigators (Chiorean, Farag, Hahn, and Matei) and planned expansion of our phase I program during the next funding period. From 2004 through mid-2007, the IUSCC supported 15 clinical trials by this mechanism. Total patient accrual is to date 132. On occasion, the Center used additional funds to support individual trials. For example, additional IUSCC funds have been used to support the laboratory correlative studies associated with a trial supported by the PSR mechanism; the PSR funding has been used to support nurses and clinical research specialists. The process has been updated during the current cycle with resulting increased number of faculty conducting investigator-initiated trials. PSR support has been prioritized to protocols that will generate preliminary data that has been (or will be) used to support R21 Quick Trials and other peer-reviewed funding applications. The process to seek funding for the conduct of pilot clinical trials was updated in 2006 and is available to all IUCC members via a continuous RFA found at http://cancer.iu.edu/research/fundinq/clin trial.php. The announcement details the fact that Protocol Specific Research funding covers the cost of a core group of research nurses and data managers (clinical research specialists) for the conduct of high priority, innovative, feasibility or proof-of-principle clinical trials. The requests for funding are to be used for early-phase testing of a candidate agent or device for the prevention or treatment of cancer. Applications are received and reviewed monthly by the Clinical Research Committee.

科学许多方面的进步包括分子生物学，基因组学和蛋白质组学导致 定义癌症的原因和新治疗方法方面的重大进展。需要密切合作 从实验室前进到诊所。这些合作和资源可用于进行 在当前的资金期间，翻译临床研究的生产力非常高。目前， CCSG为0.25 FTE研究护士和0.5 FTE临床研究专家（CRS）提供资金。 IU 西蒙癌症中心通过以下详细描述的过程分配了这笔钱，以支持研究人员 第一阶段和试点研究非常有功。 ID西蒙癌症中心还提供了 来自其他来源的额外资金，用于进行这些试验。我们预计患者人数越来越多 由于目前的资金期间招募，因此在未来的第一阶段和试点研究中累积 翻译临床研究人员（Chiorean，Farag，Hahn和Matei），并计划扩大我们的I期 在下一个资金期间计划。 从2004年到2007年中，IUSCC通过这种机制支持了15次临床试验。总应计 是迄今为止的132。有时，该中心使用额外资金来支持单个试验。例如， 额外的IUSCC资金已用于支持与试验相关的实验室相关研究 由PSR机制支持； PSR资金已用于支持护士和临床研究 专家。该过程在当前周期中已更新，导致教师数量增加 进行研究者发起的试验。 PSR支持已优先为将生成的协议 已经（或将）用于支持R21快速试验和其他同行评审资金的初步数据 申请。 2006年更新了为试验临床试验进行资金进行资金的过程，所有人都可以使用 IUCC成员通过在http://cancer.iu.edu/research/fundinq/clin trial.php上找到的连续RFA。这 公告详细介绍了协议特定研究资金涵盖核心群体的成本的事实 研究护士和数据经理（临床研究专家）进行高优先事项，创新， 可行性或原则临床试验。资金请求将用于早期测试 预防或治疗癌症的候选剂或装置。收到和审查申请 临床研究委员会每月一次。